Cogent Biosciences, Inc. (COGT) Stock
1 member of Congress disclosed 1 trade in COGT since 2022: 1 purchase and 0 sales, most recently Christopher L. Jacobs (purchase, Dec 12, 2022). 7 of the hedge funds AlphaScala tracks reported COGT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $38.55M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 5, 2026.
Which members of Congress traded Cogent Biosciences, Inc. (COGT)?
Most recent: Christopher L. Jacobs (purchase, Dec 12, 2022); records start Dec 12, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Chris Jacobs R-NY · House | 2022-12-12 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all COGT political trades →Which hedge funds own COGT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 996K | $38.55M | +41% |
| D.E. Shaw David Shaw | 922K | $35.70M | -51% |
| Millennium Management Israel Englander | 908K | $35.13M | -24% |
| Citadel Ken Griffin | 850K | $32.88M | -50% |
| Point72 Steve Cohen | 744K | $28.80M | -47% |
| Marshall Wace | 706K | $27.33M | -56% |
| Blackstone | 9K | $363.1K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Cogent Biosciences, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 27, 26 | Morris Arlene | Director | SELL | 42.3K | $1.6M |
| Aug 27, 26 | Morris Arlene | Director | SELL | 3.2K | $119K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →COGT price chart
Powered by TradingViewWhat does Cogent Biosciences, Inc. do?
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing small-molecule precision therapies for genetically defined diseases. It focuses on modulating the tumor microenvironment, particularly through inhibitors targeting colony-stimulating factor 1 receptor (CSF1R), a regulator of tumor-associated macrophages that promote tumor growth and immune evasion. The company's lead candidate, an orally bioavailable CSF1R inhibitor, is in early-stage clinical trials for solid tumors, demonstrating preclinical antitumor activity alone and combined with checkpoint inhibitors. Cogent Biosciences also advances CGT9486, a selective tyrosine kinase inhibitor designed to inhibit KIT D816V mutations and other KIT exon 17 alterations, addressing systemic mastocytosis, gastrointestinal stromal tumors, and additional solid tumor indications. Its pipeline emphasizes immune-regulatory pathways in oncology, leveraging collaborations with academic institutions and contract research organizations. Founded in 2016 and headquartered in Cambridge, Massachusetts, Cogent Biosciences plays a vital role in advancing targeted immuno-oncology treatments to address unmet needs in precision medicine.